MedTrace Logo

Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

NCT05250245 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-02-22

No results posted yet for this study

Summary

In this study, we aim to determine whether combined tolterodine and CPAP therapy is a more effective treatment for patients with OSAS than CPAP treatment only.

Conditions

Interventions

DRUG

Tolterodine Tartrate 4 MG

Tolterodine is actively being used in the treatment of over active bladder symptoms today

OTHER

Continuous positive airway pressure therapy (CPAP)

The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy

Sponsors & Collaborators

  • Yuzuncu Yıl University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-12-30
Completion
2022-01-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05250245 on ClinicalTrials.gov